Humacyte Stock Today
| HUMA Stock | USD 1.17 0.03 2.50% |
PerformanceWeakest
| Odds Of DistressRisky
|
Humacyte is trading at 1.17 as of the 8th of January 2026, a 2.5 percent decrease since the beginning of the trading day. The stock's open price was 1.2. Humacyte has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Note, on June 13, 2024, Senator Tommy Tuberville of US Senate acquired $15k to $50k worth of Humacyte's common stock.
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company was founded in 2004 and is headquartered in Durham, North Carolina. The company has 193 M outstanding shares of which 35.4 M shares are currently shorted by private and institutional investors with about 8.31 trading days to cover. More on Humacyte
Moving together with Humacyte Stock
| 0.79 | KG | Kestrel Group Symbol Change | PairCorr |
Moving against Humacyte Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Humacyte Stock Highlights
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Humacyte (HUMA) is traded on NASDAQ Exchange in USA and employs 218 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 208.44 M. Humacyte conducts business under Biotechnology sector and is part of Health Care industry. The entity has 193 M outstanding shares of which 35.4 M shares are currently shorted by private and institutional investors with about 8.31 trading days to cover.
Humacyte currently holds about 189.04 M in cash with (98.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Humacyte Probability Of Bankruptcy
Ownership AllocationHumacyte has a total of 193 Million outstanding shares. Humacyte retains significant amount of outstanding shares owned by insiders and institutional investors . On June 13, 2024, Senator Tommy Tuberville of US Senate acquired $15k to $50k worth of Humacyte's common stock.
Check Humacyte Ownership Details
Humacyte Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Humacyte market risk premium is the additional return an investor will receive from holding Humacyte long position in a well-diversified portfolio.
| Mean Deviation | 3.78 | |||
| Standard Deviation | 4.78 | |||
| Variance | 22.83 | |||
| Risk Adjusted Performance | (0.05) |
Humacyte Stock Against Markets
Humacyte Corporate Management
| Harold Alterson | Senior Quality | Profile | |
| Sabrina Osborne | Executive People | Profile | |
| Dale Sander | Chief CFO | Profile | |
| Heather Connelly | Senior Quality | Profile | |
| William Scheessele | Chief Officer | Profile | |
| Yang MD | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.